Health Economics›Breast cancer›Advanced or metastatic disease all lines of therapy

Advanced or metastatic disease all lines of therapy

Breast cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alpelisib and Fulvestrant Variant #01	PIK3CA	R 29 435	28d	~11.0 mo	—	~3	~R 61 098 PFS proxy · indirect	1
Fulvestrant monotherapy Variant #01	PIK3CA	R 2 721	28d	~5.5 mo	~39.4 mo	~2	~R 5 442 PFS proxy · indirect	37
Paclitaxel monotherapy Variant #02	PIK3CA	R 734	28d	—	7.5 mo	7	R 5 141 PFS proxy	1

3 of 3 regimens shown